September 25, 2020 06:09 AM EDT

Palladio bags $20 million Series B to topple a problematic kidney disease drug

Nicole DeFeudis

Editor

Palladio Biosciences just took one step further in its quest to topple Otsuka’s Samsca with its own — it hopes safer — autosomal dominant polycystic kidney disease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Palladio bags $20 million Series B to topple a problematic kidney disease drug

Nicole DeFeudis

Editor

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Applied Therapeutics' rare disease drug gets a CRL

Pal­la­dio bags $20 mil­lion Se­ries B to top­ple a prob­lem­at­ic kid­ney dis­ease drug

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Palladio bags $20 million Series B to topple a problematic kidney disease drug

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Applied Therapeutics' rare disease drug gets a CRL